Incyte Corporation heads into the final stretch before its July 28 Q2 print with an unusual split in signals — short sellers are covering at the fastest pace in months, yet options traders are hedging more than they have all spring.
The short-covering story is the clearest near-term development. SI as a percentage of free float has dropped from a peak of 7.19% on April 28 to 6.38% now — a meaningful six-week unwind that pulled estimated shares short down nearly 6% over the past week alone. The trend is consistent: every week since late April has seen net covering. Days to cover remain elevated at 7.05 per the latest FINRA data, so this is not a crowded short being squeezed — it is a deliberate retreat. Availability is extremely loose at over 1,800% of outstanding short interest, meaning the borrow market poses no friction for new shorts if sentiment shifts. Cost to borrow has drifted higher by about 28% over the past week but remains negligible at 0.42% annualised — there is no squeeze pressure in the lending market.
Options positioning tells a more cautious story. The put/call ratio has climbed to 1.25, above its 20-day average of 1.14 and running near the more defensive end of its recent range — though still well below the 52-week high of 1.67. That shift over the past two sessions is notable. The PCR was sitting comfortably around 1.09 to 1.15 for most of May before jumping alongside the stock's 3.6% weekly slide to $95.60. Options traders appear to be adding downside protection in response to the price weakness rather than signalling a fundamental re-assessment.
The Street has been mildly constructive since Q1 results landed on April 28. The stock gained 3.5% on the day of the print. Two analysts raised targets in its wake — Stifel lifted to $123 while keeping a Buy, and Oppenheimer nudged its target to $90, though it maintains a neutral Perform rating. Those two moves capture the bull-bear divide well: buyers see Opzelura's atopic dermatitis and vitiligo franchise expanding the revenue base beyond the Jakafi royalty stream, while sceptics note the stock already trades close to neutral targets. The consensus sits at Hold with a mean target near $108, implying roughly 13% upside from current levels. UBS and Jefferies both cut targets to $94 earlier in the spring — Jefferies downgraded to Hold from Buy in March — so the $94–$95 zone has become a natural anchor for those with more cautious views. Valuation has compressed alongside the price drift: the trailing P/E has eased to 11.6x, down almost a full turn over 30 days, while EV/EBITDA is running at 8x. The earnings yield factor ranks in the 70th percentile, suggesting the stock is not expensive by biotech standards. EPS momentum over 30 and 90 days ranks in the 76th and 71st percentiles respectively — the earnings revision picture remains firm even as the share price has softened.
The ownership picture is worth a brief note. Baker Bros. Advisors holds 15.4% of shares and added modestly as recently as May 8. Wellington Management added over 2.5 million shares in the most recently reported quarter — one of the more active institutional moves in the holder list. On the insider side, divisional President Pablo Cagnoni has sold around 18,600 shares three times since February — February 19, March 17, and April 17 — at prices ranging from $94 to $101, consistent with a scheduled disposition programme rather than a directional call.
The next major marker is the Q2 print on July 28. The Q1 reaction — a 3.5% one-day gain followed by a smaller 1.8% five-day continuation — sets a modest baseline expectation. What to watch between now and then is whether the options PCR continues to climb above 1.25, which would signal broader hedging demand, and whether the short-covering trend stalls or reverses as the stock tests the $94–$95 support zone that sceptical analysts have flagged as fair value.
See the live data behind this article on ORTEX.
Open INCY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
